- Early-bird tickets now on sale for a generative AI–powered exhibition featuring real-time character interaction
- Debuting June 18, the exhibition introduces AI-driven storytelling through live interactions with Baby Shark characters
Download images here
SEOUL, April 16, 2026 /PRNewswire/ -- The Pinkfong Company, the global entertainment company behind Baby Shark, today announced early-bird ticket sales for "Baby Shark The Experience: Unlock the Secret Ocean," a new AI-powered interactive exhibition that blends generative AI technology with immersive storytelling.
Opening June 18 at Dongdaemun Design Plaza (DDP)—one of Seoul's premier cultural and design landmarks—the exhibition invites global fans into the underwater world of Baby Shark through real-time AI-driven character interactions and personalized storytelling. Early-bird tickets are now available through official ticketing platforms, offering discounts of up to 50 percent for a limited time.
Spanning approximately 18,000 square feet, the exhibition features around 20 interactive experiences that bring the Baby Shark universe to life. Visitors can explore immersive underwater-inspired environments while interacting with characters that respond dynamically to their voices, facial expressions, and movements, creating a personalized experience throughout the exhibition.
The experience integrates large language models (LLMs), speech recognition, voice synthesis, and computer vision, enabling characters to respond in real time while engaging in dynamic conversations. One of the exhibition's signature features allows guests to create their own version of the iconic Baby Shark song through an AI-powered music experience, adding a personalized creative layer to the exhibition. The experience also supports four languages—English, Chinese, Japanese, and Korean—allowing visitors from around the world to participate seamlessly.
"By combining AI technology with character storytelling, this project introduces a new kind of interactive entertainment experience," said Gemma Joo, Chief Business Officer at The Pinkfong Company. "We hope it offers audiences of all ages a glimpse into how AI can create more immersive and emotionally engaging ways to experience beloved characters."
About The Pinkfong Company
The Pinkfong Company is a global entertainment company that delivers content and entertaining experiences around the world. Driven by award-winning brands and IPs, the company has created and distributed a range of content across genres and formats including original animated series, world live tours, interactive games, and more. Believing in the power of entertaining and engaging content, The Pinkfong Company is committed to connecting people around the world and bringing joy and inspiration to worldwide audiences of all ages. For more information, please visit the website or follow the company on LinkedIn.
Media Contact
Hailey Kim
Communications Manager
The Pinkfong Company
hailey@pinkfong.com
Download images here
SEOUL, April 16, 2026 /PRNewswire/ -- The Pinkfong Company, the global entertainment company behind Baby Shark, today announced early-bird ticket sales for "Baby Shark The Experience: Unlock the Secret Ocean," a new AI-powered interactive exhibition that blends generative AI technology with immersive storytelling.
Opening June 18 at Dongdaemun Design Plaza (DDP)—one of Seoul's premier cultural and design landmarks—the exhibition invites global fans into the underwater world of Baby Shark through real-time AI-driven character interactions and personalized storytelling. Early-bird tickets are now available through official ticketing platforms, offering discounts of up to 50 percent for a limited time.
Spanning approximately 18,000 square feet, the exhibition features around 20 interactive experiences that bring the Baby Shark universe to life. Visitors can explore immersive underwater-inspired environments while interacting with characters that respond dynamically to their voices, facial expressions, and movements, creating a personalized experience throughout the exhibition.
The experience integrates large language models (LLMs), speech recognition, voice synthesis, and computer vision, enabling characters to respond in real time while engaging in dynamic conversations. One of the exhibition's signature features allows guests to create their own version of the iconic Baby Shark song through an AI-powered music experience, adding a personalized creative layer to the exhibition. The experience also supports four languages—English, Chinese, Japanese, and Korean—allowing visitors from around the world to participate seamlessly.
"By combining AI technology with character storytelling, this project introduces a new kind of interactive entertainment experience," said Gemma Joo, Chief Business Officer at The Pinkfong Company. "We hope it offers audiences of all ages a glimpse into how AI can create more immersive and emotionally engaging ways to experience beloved characters."
About The Pinkfong Company
The Pinkfong Company is a global entertainment company that delivers content and entertaining experiences around the world. Driven by award-winning brands and IPs, the company has created and distributed a range of content across genres and formats including original animated series, world live tours, interactive games, and more. Believing in the power of entertaining and engaging content, The Pinkfong Company is committed to connecting people around the world and bringing joy and inspiration to worldwide audiences of all ages. For more information, please visit the website or follow the company on LinkedIn.
Media Contact
Hailey Kim
Communications Manager
The Pinkfong Company
hailey@pinkfong.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Baby Shark Meets Generative AI in a New Interactive Experience
|
Lunit highlights enterprise AI adoption and FDA-cleared advancements at SBI 2026
SEOUL, South Korea, April 16, 2026 /PRNewswire/ -- At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced accelerating clinical adoption across the U.S., a full-scale enterprise deployment of its AI-powered breast cancer ecosystem, and FDA clearance of its next-generation 3D mammography AI.
Lexington Clinic Adopts Full Breast Cancer Ecosystem
Lexington Clinic, Central Kentucky's largest and oldest physician-owned multi-specialty medical group (serving more than 350 providers), has implemented Lunit's complete AI-powered breast cancer ecosystem.
The deployment spans:
- Detection with Lunit INSIGHT® Breast Suite for mammography (MMG) and digital breast tomosynthesis (DBT)
- Quality optimization with Analytics™ and Volpara® Live™
- Volumetric breast density assessment with Volpara® Scorecard™
- Risk assessment with Risk Pathways™, integrated into clinical workflows
- Mammography tracking with Patient Hub™
The implementation signals a shift toward end-to-end AI integration across the breast care continuum—from risk to detection to quality—within a single software suite.
"Our goal is to deliver the highest standard of care while keeping workflows efficient and consistent," said Angie Hall, Breast Center Manager at Lexington Clinic. "Bringing risk, detection, and quality into one ecosystem improves coordination across our team and supports more confident, earlier decision-making for every patient."
Adoption Across the Americas Surpasses 330 Sites
Over the past year, Lunit has expanded to more than 330 screening sites across the Americas, supporting approximately one million screening mammograms annually.
The milestone highlights a broader industry shift: while AI validation is well established, real-world adoption at scale is now the key differentiator.
"Across the Americas, we're seeing a clear move from evaluation to enterprise-wide implementation," said Craig Hadfield, CEO of Lunit International. "Providers are moving beyond pilots into daily clinical use. Reaching more than 330 sites and supporting one million screenings annually reflects sustained, real-world adoption—where AI is delivering value in routine practice."
Real-World Clinical Impact: Radiology Consultants of Iowa
At Radiology Consultants of Iowa (RCI), one of the largest radiology groups in the state, Lunit INSIGHT DBT is already embedded in routine clinical workflows, demonstrating the impact of AI beyond the study setting.
"After six months of using AI in our daily workflow, it's become part of how we read," said Robert J. Dolan, DO, breast imaging specialist at RCI. "It gives us added confidence—especially in subtle cases—and helps ensure we don't miss what matters most."
At SBI, Dr. Dolan will review cases each day in Lunit's booth, highlighting where AI positively impacts his interpretation, giving attendees a chance to discuss real-world adoption.
FDA Clearance of Next-Generation 3D AI with Current-Prior Comparison
As providers move into routine AI use, flexibility in how algorithms are deployed is becoming increasingly important. Lunit announced that Version 1.2 of its 3D mammography algorithm has received clearance from the U.S. Food and Drug Administration (FDA).
The updated version introduces current-prior comparisons and multiple operating thresholds, enabling providers to tailor AI performance to their clinical environment.
Key enhancements include:
- Current-prior comparison (CPC) provides AI findings for the current exam and up to two prior exams
- Three selectable thresholds, supporting different sensitivity and specificity trade-offs
- Access to Volpara® Scorecard™ volumetric breast density measures along with AI scores
These updates reinforce Lunit's focus on practical usability—giving clinicians greater control over how AI is applied in daily practice.
###
About Lunit
Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.
Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.
Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
Lunit highlights enterprise AI adoption and FDA-cleared advancements at SBI 2026
SEOUL, South Korea, April 16, 2026 /PRNewswire/ -- At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced accelerating clinical adoption across the U.S., a full-scale enterprise deployment of its AI-powered breast cancer ecosystem, and FDA clearance of its next-generation 3D mammography AI.
Lexington Clinic Adopts Full Breast Cancer Ecosystem
Lexington Clinic, Central Kentucky's largest and oldest physician-owned multi-specialty medical group (serving more than 350 providers), has implemented Lunit's complete AI-powered breast cancer ecosystem.
The deployment spans:
- Detection with Lunit INSIGHT® Breast Suite for mammography (MMG) and digital breast tomosynthesis (DBT)
- Quality optimization with Analytics™ and Volpara® Live™
- Volumetric breast density assessment with Volpara® Scorecard™
- Risk assessment with Risk Pathways™, integrated into clinical workflows
- Mammography tracking with Patient Hub™
The implementation signals a shift toward end-to-end AI integration across the breast care continuum—from risk to detection to quality—within a single software suite.
"Our goal is to deliver the highest standard of care while keeping workflows efficient and consistent," said Angie Hall, Breast Center Manager at Lexington Clinic. "Bringing risk, detection, and quality into one ecosystem improves coordination across our team and supports more confident, earlier decision-making for every patient."
Adoption Across the Americas Surpasses 330 Sites
Over the past year, Lunit has expanded to more than 330 screening sites across the Americas, supporting approximately one million screening mammograms annually.
The milestone highlights a broader industry shift: while AI validation is well established, real-world adoption at scale is now the key differentiator.
"Across the Americas, we're seeing a clear move from evaluation to enterprise-wide implementation," said Craig Hadfield, CEO of Lunit International. "Providers are moving beyond pilots into daily clinical use. Reaching more than 330 sites and supporting one million screenings annually reflects sustained, real-world adoption—where AI is delivering value in routine practice."
Real-World Clinical Impact: Radiology Consultants of Iowa
At Radiology Consultants of Iowa (RCI), one of the largest radiology groups in the state, Lunit INSIGHT DBT is already embedded in routine clinical workflows, demonstrating the impact of AI beyond the study setting.
"After six months of using AI in our daily workflow, it's become part of how we read," said Robert J. Dolan, DO, breast imaging specialist at RCI. "It gives us added confidence—especially in subtle cases—and helps ensure we don't miss what matters most."
At SBI, Dr. Dolan will review cases each day in Lunit's booth, highlighting where AI positively impacts his interpretation, giving attendees a chance to discuss real-world adoption.
FDA Clearance of Next-Generation 3D AI with Current-Prior Comparison
As providers move into routine AI use, flexibility in how algorithms are deployed is becoming increasingly important. Lunit announced that Version 1.2 of its 3D mammography algorithm has received clearance from the U.S. Food and Drug Administration (FDA).
The updated version introduces current-prior comparisons and multiple operating thresholds, enabling providers to tailor AI performance to their clinical environment.
Key enhancements include:
- Current-prior comparison (CPC) provides AI findings for the current exam and up to two prior exams
- Three selectable thresholds, supporting different sensitivity and specificity trade-offs
- Access to Volpara® Scorecard™ volumetric breast density measures along with AI scores
These updates reinforce Lunit's focus on practical usability—giving clinicians greater control over how AI is applied in daily practice.
###
About Lunit
Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.
Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.
Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Lunit Surpasses 330+ Sites and 1M Annual Screenings as Breast Imaging AI Moves into Clinical Practice
